MBC BioLabs Nucleic Acid Medicine Innovation Forum

​The MBC BioLabs Nucleic Acid Medicines Innovation Forum is focused on strengthening community among the founders, executives, and investors in our ecosystem. This event will bring together startups reimagining how nucleic acids are used to diagnose and treat disease. We’re excited to create space for relationship-driven engagement that helps our companies grow together.

​Presenting startups include:

• ​Junevity: Pioneering RESET, the first siRNA cell reprogramming platform leveraging human omics data, genetic linkages, machine learning, and siRNA.

• ​Engage Bio: Developing Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine.

• ​Form Bio: Transforming the genetic medicine pipeline from concept to clinic with AI‑driven design and analysis.

• ​Therna Biosciences: Building a new era of programmable RNA therapeutics by integrating deep RNA biology with generative AI.

• ​Delve Bio: Advancing metagenomic next-generation sequencing (mNGS) tests for infectious diseases.

• ​Gigamune: Using high-throughput genomics and artificial intelligence to identify CARs and cell-tropic antibodies for treatment of multiple myeloma, acute myeloblastic leukemia (AML), and inherited blood disorders.

• ​Portal: Developing a universal cell engineering solution for a diverse matrix of cell types and cargoes, including mRNA, siRNA, saRNA.

​Poster presentations by: nCode Biosciences, Nanotrace, Eigen Bio, Motley Bio, AmplifiDx, Vivid BioInnovations, Resero Bio, Iris Medicine, Nexocura, Neovariant Bio.

​This is an invitation-only event with a thoughtfully curated group of investors, business development teams, and founders shaping the landscape. Expect meaningful dialogue, new connections, and startups presenting what’s next in the science of nucleic acid medicines.

Agenda and more details to follow.